Recent progress in plantibody technology

Current Pharmaceutical Design

Volumn 11, Issue 19, 2005, Pages 2439-2457

  Stoger, E ^a   Sack, M ^a   Nicholson, L ^b   Fischer, R ^a   Christou, P ^c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b JOHN INNES CENTRE   (United Kingdom)

^c FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; SECRETORY IMMUNOGLOBULIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VEGETABLE PROTEIN;

ALFALFA; ANTIBODY PRODUCTION; BACTERIUM CULTURE; BARLEY; BIOCHEMISTRY; BIOREACTOR; BIOSAFETY; CEREAL; CHLAMYDOMONAS REINHARDTII; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG INDUSTRY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSFORMATION; GLYCOSYLATION; GOOD MANUFACTURING PRACTICE; HUMAN; LEGUME; MAIZE; MAMMAL CELL; NONHUMAN; PATENT; PATIENT CARE; PHYSCOMITRELLA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REVIEW; RHIZOBIUM RADIOBACTER; SAFETY; SOYBEAN; TECHNOLOGY; TOBACCO; TRANSGENIC PLANT; WHEAT;

ANIMALS; FORECASTING; HUMANS; PLANTIBODIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 21044446134     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367535     Document Type: Review

References (148)

1. Fleckenstein G, Osmers R, Puchta J. Monoclonal antibodies in solid tumours: approaches to therapy with emphasis on gynaecological cancer. Med Oncol 1998; 15: 212-21.
2. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002; 324: 14-30.
3. Markowska J. Monoclonal antibodies in the treatment of ovarian cancer. Eur J Gynaecol Oncol 2003; 24: 7-11.
4. Köhler G. Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
5. Pluckthun A, Krebber A, Krebber C, Horn U, Knupfer U, Wenderoth R, et al. In: McCafferty J, Hoogenboom HR, Chiswell DJ Ed, Antibody engineering: A practical approach. New York, Oxford University Press. 1996; 203.
6. Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr Opin Biotechnol 2001; 12: 180-7.
7. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263: 133-47.
8. Ma JKC, Drake PM, Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003; 4: 794-805.
9. Giddings G. Transgenic plants as protein factories. Curr Opin Biotechnol 2001; 12: 450-4.
10. Stoger E, Sack M, Fischer R, Christou P. Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol 2002; 13: 161-6.
11. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceutical and edible vaccines in plants. Trends Plant Sci 2001; 6: 219-26.
12. Twyman RM, Stoger E, Schillberg S, Christou P, Fischer R. Molecular farming in plants: Host systems and expression technology. Trends Biotechnol 2003; 21: 570-8.
13. Fischer R, Stoger E, Schillberg S, Christou P, Twyman RM. Plant based production of biopharmaceuticals. Curr Opin Plant Biol 2004; 7: 152-8.
14. Schillberg S, Emans N, Fischer R. Antibody molecular farming in plants and plant cells. Phytochem Rev 2002; 1: 45-54.
15. Schillberg S, Fischer R, Emans N. Molecular farming of recombinant antibodies in plants. Cell Mol Life Sci 2003; 60: 433-45.
16. Valdes R, Gomez L, Padilla S, Brito J, Reyes B, Alvarez T, et al. Large-scale purification of an antibody directed against hepatitis B surface antigen from transgenic tobacco plants. Biochem Biophys Res Commun 2003; 308: 94-100.
17. Khoudi H, Laberge S, Ferullo JM, Bazin R, Darveau A, Castonguay Y, et al. Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotechnol Bioeng 1999; 64: 135-43.
18. Bardor M, Loutelier-Bourhis C, Paccalet T, Cosette P, Fitchette A-C, Vézina L-P, et al. Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures. Plant Biotechnol J 2003; 1: 451-62.
19. Conrad U, Fiedler U. Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol Biol 1998; 38: 101-9.
20. Stoger E, Sack M, Perrin Y, Vaquero C, Torres E, Twyman RM, et al. Practical considerations for pharmaceutical antibody production in different crop systems. Mol Breeding 2000; 9: 149-158.
21. Stoger E, Vaquero C, Torres E, Sack M, Nicholson L, Drossard J, et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000; 42: 583-90.
22. Schunmann PHD, Coia G, Waterhouse PM. Biopharming the SimpliRED™ HIV diagnostic reagent in barley, potato and tobacco. Mol Breeding 2002; 9: 113-21.
23. Hood EE, Woodard SL, Horn ME. Monoclonal antibody manufacturing in transgenic plants - myths and realities. Curr Opin Biotechnol 2002; 13: 630-5.
24. Perrin Y, Vaquero C, Gerrard I, Sack M, Drossard J, Stöger E, et al. Transgenic pea seeds as bioreactors for the production of single chain Fv antibody fragment (scFV) used in cancer diagnosis and therapy. Mol Breeding 2000; 6: 345-52.
25. Saalbach I, Giersberg M, Conrad U. High-level expression of a single-chain Fv fragment (scFv) antibody in transgenic pea seeds. J Plant Physiol 2001; 158: 529-33.
26. Zeitlin L, Olmsted SS, Moench TR, Co MS, Martinell BJ, Paradkar VM, et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nature Biotechnol 1998; 16: 1361-4.
27. Hood EE, Witcher DR, Maddock S, Meyer T, Baszczynski C, Bailey M, et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol Breeding 1997; 3: 291-306.
28. Witcher D, Hood EE, Peterson D, Bailey M, Bond D, Kusnadi A, et al. Commercial production of β-glucuronidase (GUS): a model system for the production of proteins in plants. Mol Breeding 1998; 4: 301-12.
29. Artsaenko O, Peisker M, zur Nieden U, Fiedler U, Weiler EW, Müntz K, et al. Expression of a single-chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco. Plant J 1995; 8: 745-50.
30. De Wilde C, Peeters K, Jacobs A, Peck I, Depicker A. Expression of antibodies and Fab fragments in transgenic potato plants: a case study for bulk production in crop plants. Mol Breeding 2002; 9: 271-82.
31. Franklin SE and Mayfield SP. Prospects for molecular farming in the green alga Chlamydomonas reinhardtii. Curr Opin Plant Biol 2004; 7: 1-7.
32. Mayfield SP, Franklin SE, Lerner RA. Expression and assembly of a fully active antibody in algae. Proc Natl Acad Sci USA 2003; 100: 438-42.
33. Decker EL, Reski R. The moss bioreactor. Curr Opin in Plant Biol 2004; 7: 166-170.
34. Gomord V, Faye L. Posttranslational modification of therapeutic proteins in plants. Curr Opin Plant Biol, 2004, 7: 171-181.
35. Gasdaska JR, Spencer D, Dickey L. Advantages of therapeutic protein production in the aquatic plant Lemna. Bioprocess J 2003; 2: 49-56.
36. Doran PM. Foreign protein production in plant tissue cultures. Curr Opin Biotechnol 2000; 11: 199-204.
37. Fischer R, Emans N, Schuster F, Hellwig S, Drossard J. Towards molecular farming in the future: using plant-cell-suspension cultures as bioreactors. Biotechnol Appl Biochem 1999; 30: 109-12.
38. Sharp JM, Doran PM. Strategies for enhancing monoclonal antibody accumulation in plant cell and organ cultures. Biotechnol Progr 2001; 17: 979-92.
39. Sharp JM, Doran PM. Characterization of monoclonal antibody fragments produced by plant cells. Biotechnol Bioeng 2001; 73: 338-346.
40. Torres E, Vaquero C, Nicholson L, Sack M, Stoger E, Drossard J, et al. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies. Transgenic Res 1999; 8: 441-9.
41. Christou P. Particle gun-mediated transformation. Curr Opin Biotechnol 1993; 4: 135-41.
42. Vaquero C, Sack M, Chandler J, Drossard J, Schuster F, Schillberg S, et al. Transient expression of a tumor-specific single chain fragment and a chimeric antibody in tobacco leaves. Proc Natl Acad Sci USA 1999; 96: 11128-33.
43. Larrick JW, Yu L, Naftzger C, Jaiswal S, Wycoff K. Production of secretory IgA antibodies in plants. Biomolecular Eng 2001; 18: 87-94.
44. Hanson B, Engler D, Moy Y, Newman B, Ralston E, Gutterson N. A simple method to enrich an Agrobacterium-transformed population for plants containing only T-DNA sequences. Plant J. 1999; 19: 727-34.
45. Stewart CN Jr, Halfhill MD, Warwick SI. Transgene introgression from genetically modified crops to their wild relatives. Nat Rev Genet 2003; 4: 806-17.
46. Fu X, Duc LT, Fontana S, Bong BB, Tinjuangjun P, Sudhakar D, et al. Linear transgene constructs lacking vector backbone sequences generate low-copy-number transgenic plants with simple integration patterns. Transgenic Res 2000; 9: 11-19.
47. Loc NT, Tinjuangjun P, Gatehouse AMR, Christou P, Gatehouse JA. Linear transgene constructs lacking vector backbone sequences generate transgenic rice plants which accumulate higher levels of proteins conferring insect resistance. Mol Breeding 2002; 9: 231-44.
48. Breitler JC, Labeyrie A, Meynard D, Legavre T, Guiderdoni E. Efficient microprojectile bombardment-mediated transformation of rice using gene cassettes. Theor Appl Genet 2002; 104: 709-19.
49. Clough SJ, Bent A. Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana. Plant J 1998; 16: 735-43.
50. McCormick AA, Reinl SJ, Cameron TI, Vojdani F, Fronefield M, Levy R, et al. Individualized human scFv vaccines produced in plants: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 2003; 278: 95-104.
51. Roggero P, Ciuffo M, Benvenuto E, Franconi R: The expression of a single-chain Fv antibody fragment in different plant hosts and tissues by using Potato virus X as a vector. Protein Expr Purif 2001, 22: 70-74.
52. Verch T, Yusibov V, Koprowski H: Expression and assembly of a full-length monoclonal antibody in plants using a plant virus vector. J Immunol Methods 1998; 220: 69-75.
53. De Jaeger G, Scheffer S, Jacobs A, Zambre M, Zobell O, Goossens A, et al. Boosting heterologous protein production in transgenic dicotyledonous seeds using Phaseolus vulgaris regulatory sequences. Nature Biotechnol 2002; 20: 1265-8.
54. Padidam M. Chemically regulated gene expression in plants. Curr Opin Plant Biol 2003; 6: 169-177.
55. Cramer CL, Boothe JG, Oishi KK. Transgenic plants for therapeutic proteins: linking upstream and downstream technologies. Curr. Top. Microbiol. & Immunol. 1999; 240: 95-118.
56. Drake PMW, Chargeleuge DM, Vine ND, van Dolleweerd CJ, Obregon P, Ma JKC. Rhizosecretion of a monoclonal antibody protein complex from transgenic tobacco roots. Plant Mol Biol 2003; 52: 233-41.
57. Schillberg S, Zimmermann S, Findlay K, Fischer R. Plasma membrane display of anti-viral single chain Fv fragments confers resistance to tobacco mosaic virus. Mol Breeding 2000; 6: 317-26.
58. Vine ND, Drake P, Hiatt A, Ma JK: Assembly and plasma membrane targeting of recombinant immunoglobulin chains in plants with a routine immunoglobulin transmembrane sequence. Plant Mol Biol 2001, 45: 159-167.
59. Haas IG and Wabl MR. Immunoglobulin heavy chain binding protein. Nature 1983; 306: 387-389.
60. Lee Y-K, Brewer JW, Hellman R and Hendershot LM. BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Mol Biol Cell 1999; 10: 2209-2219.
61. Hiatt A, Cafferkey R, Bowdish K. Production of antibodies in transgenic plants. Nature 1989; 342: 76-78.
62. Baum TJ, Hiatt A, Parrott WA, Pratt LH, Hussey RS. Expression in tobacco of a functional monoclonal antibody specific to stylet secretions of the root-knot nematode. Mol Plant Microbe Interact 1996; 9: 382-7.
63. Ma JK, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, et al. Generation and assembly of secretory antibodies in plants. Science 1995; 268: 716-9.
64. Frigerio L, Vine ND, Pedrazzini E, Hein MB, Wang F, Ma JK-C, et al. Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants. Plant Physiol 2000; 123: 1483-1493.
65. Hadlington JL, Santoro A, Nuttall J, Denecke J, Ma JK, Vitale A, et al. The C-terminal extension of a hybrid immunoglobulin A/G heavy chain is responsible for its Golgi-mediated sorting to the vacuole. Mol Biol Cell. 2003; 14: 2592-602.
66. Nuttall J, Vine N, Hadlington JL, Drake P, Frigerio L, Ma JKC. ER-resident chaperone interactions with recombinant antibodies in transgenic plants. Eur J Biochem 2002; 269: 6042-51.
67. De Jaeger G, Buys E, Eeckhout D, De Wilde C, Jacobs A, Kapila J, et al. High-level accumulation of single-chain variable fragments in the cytosol of transgenic Petunia hybrida. Eur J Biochem 1999; 259: 42-34.
68. Worn A. and Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001; 305: 989-1010.
69. Jobling SA, Jarman C, Teh MM, Holmberg N, Blake C, Verhoeyen ME. Immunomodulation of enzyme function in plants by single domain antibody fragments. Nature Biotechnol 2003; 21: 77-80.
70. Schouten A, Roosien J, Bakker J, Schots A. Formation of disulfide bridges by a single-chain Fv antibody in the reducing ectopic environment of the plant cytosol. J Biol Chem 2002; 277: 19339-19345.
71. Torres E, Gonzalez-Melendi P, Stoger F, Shaw P, Twyman RM, Nicholson L, et al. Native and artificial reticuloplasmins co-accumulate in distinct domains of the endoplasmic reticulum and in post-endoplasmic reticulum compartments. Plant Physiol 2001; 127: 1212-23.
72. Moloney M, Boothe J, Van Rooijen G. Oil bodies and associated proteins as affinity matrices. January 21, 2003; US Patent 6509453. SemBioSys Genetics Inc.
73. Sriraman R, Bardor M, Sack M, Vaquero C, Faye L, Fischer R, et al. Retention of recombinant antibodies in the plant endoplasmic reticulum results in production of plantibodies lacking plant specific core-xylose and core-a(1,3)-fucose residues. Plant Biotechnol J 2004; (in press).
74. Cabanes-Macheteau M, Fitchette-Lainé AC, Loutelier-Bourhis C, Lange C, Vine NK, Ma JKC, et al. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology 1999; 9: 365-372.
75. Peeters K, De Wilde C, Depicker A: Highly efficient targeting and accumulation of a F(ab) fragment within the secretory pathway and apoplast of Arabidopsis thaliana. Eur J Biochem 2001, 268: 4251-4260.
76. Hiatt A. Antibodies produced in plants. Nature 1990; 344: 469-70.
77. Kusnadi AR, Nikolov ZL, Howard JA. Production of recombinant proteins in transgenic plants: Practical considerations. Biotechnol Bioeng 1997; 56: 473-84.
78. Fischer R, Twyman RM, Schillberg S. Production of antibodies in plants and their use for global health. Vaccine 2003; 21: 820-5.
79. Chadd HE, Chamow SM: Therapeutic antibody expression technology. Curr Opin Biotechnol 2001, 12: 188-194.
80. Baez J, Russell D, Craig J. Corn Seed Production of Therapeutic Proteins Moves Forward: One Company's Experience. Biopharm 2000, 13: 50-54.
81. Kapila J, De Rycke R, van Montagu M, Angenon G. An Agrobacterium mediated transient gene expression system for intact leaves. Plant Sci 1996; 122: 101-8.
82. Vaquero C, Sack M, Schuster F, Finnern R, Drossard J, Schumann D, et al. A carcinoembryonic antigen-specific diabody produced in tobacco. FASEB J 2002; 16: 408-10.
83. Kathuria S, Sriraman R, Nath R, Sack M, Pal R, Artsaenko O, et al. Efficacy of plant-produced recombinant antibodies against HCG. Hum Reprod 2002; 17: 2054-61.
84. Kazemier B, de Haard H, Boender P, van Gemen B, Hoogenboom H. Determination of active single chain antibody concentrations in crude periplasmic fractions. J Immunol Methods 1996; 194: 201-9.
85. Richalet-Secordel PM, Rauffer-Bruyere N, Christensen LL, Ofenloch-Haehnle B, Seidel C, Van Regenmortel MH. Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997; 249: 165-73.
86. Ma JK, Hikmat BY, Wycoff K, Vine ND, Chargelegue D, Yu L, et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nature Med 1998; 4: 601-6.
87. Ko K, Tekoah Y, Rudd PM, Harvey DJ, Dwek RA, Spitsin S, et al. Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci USA 2003; 100: 8013-8.
88. Jefferis R. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J Immunol Methods 1998; 213: 113-30.
89. Stevens LH, Stoopen GM, Elbers IJW, Molthoff JW, Bakker HAC, Lommen A, et al. Effect of Climate Conditions and Plant Developmental Stage on the Stability of Antibodies Expressed in Transgenic Tobacco. Plant Physiology 2000, 124: 173-242.
90. Düring K, Hippe S, Kreuzaler F, Schell J. Synthesis and selfassembly of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Mol Biol 1990; 15: 281-93.
91. De Neve M, De Loose M, Jacobs A, Van Houdt H, Kaluza B, Weidle U, et al. Assembly of an antibody and its derived antibody fragment in Nicotiana and Arabidopsis. Transgenic Res 1993; 2: 227-37.
92. Lund J, Tanaka T, Takahashi N, Sarmay G, Arata Y, Jefferis R. A protein structural change in aglycosylated IgG3 correlates with loss of huFc gamma R1 and huFc gamma R111 binding and/or activation. Mol Immunol 1990; 27: 1145-53.
93. Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 1998; 160: 3393-402.
94. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of focose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733-40.
95. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73.
96. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, Dwek RA. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 1997; 36: 1370-80.
97. Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, et al. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem 2001; 276: 45539-47.
98. Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003; 325: 979-89.
99. Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10: 477-86.
100. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5: 813-22.
101. Kunkel JP, Jan DC, Jamieson JC, Butler M. Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J Biotechnol 1998; 62: 55-71.
102. Fotinopoulou A, Meyers T, Varley P, Turner G. Screening for glycosylation changes on recombinant human IgG using lectin methods. Biotechnol Appl Biochem 2003; 37: 1-7.
103. Elbers IJ, Stoopen GM, Bakker H, Stevens LH, Bardor M, Molthoff JW, et al. Influence of growth conditions and developmental stage on N-glycan heterogeneity of transgenic immunoglobulin G and endogenous proteins in tobacco leaves. Plant Physiol 2001; 126: 1314-22.
104. Ramirez N, Rodriguez M, Ayala M, Cremata J, Perez M, Martinez A, et al. Expression and characterization of an anti-(hepatitis B surface antigen) glycosylated mouse antibody in transgenic tobacco (Nicotiana tabacum) plants and its use in the immunopurification of its target antigen. Biotechnol Appl Biochem 2003; 38: 223-30.
105. Sriraman R, Bardor M, Sack M, Vaquero C, Faye L, Fischer R, et al. Retention of recombinant antibodies in the plant endoplasmic reticulum results in production of plantibodies lacking plant specific core-xylose and core-a(1,3)-fucose residues. Plant Biotechnol J 2004; (in press).
106. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med. 1988; 167: 1731-6.
107. Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J 1997; 14: 401-5.
108. Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40: 585-93.
109. Tao MH, Morrison SL. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J Immunol 1989; 143: 2595-601.
110. Dorai H, Mueller BM, Reisfeld RA, Gillies SD. Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. Hybridoma 1991; 10: 211-7.
111. Hand PH, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, et al. Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol Immunother 1992; 35: 165-74.
112. Wawrzynczak EJ, Cumber AJ, Parnell GD, Jones PT, Winter G. Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol 1992; 29: 213-20.
113. Wawrzynczak EJ, Denham S, Parnell GD, Cumber AJ, Jones PT, Winter G. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse. Mol Immunol 1992; 29: 221-7.
114. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002; 263: 133-47.
115. Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000; 37: 697-706.
116. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnol 1999; 17: 176-80.
117. Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechnol Bioeng 2001; 74: 288-94.
118. Wilson IB, Zeleny R, Kolarich D, Staudacher E, Stroop CJ, Kamerling JP, et al. Analysis of Asn-linked glycans from vegetable foodstuffs: widespread occurrence of Lewis a, core alpha1, 3-linked fucose and xylose substitutions. Glycobiology 2001; 11: 261-74.
119. Lerouge P, Cabanes-Macheteau M, Rayon C, Fischette-Laine AC, Gomord V, Faye L. N-glycoprotein biosynthesis in plants: recent developments and future trends. Plant Mol Biol 1998; 38: 31-48.
120. Van Ree R, Cabanes-Macheteau M, Akkerdaas J, Milazzo JP, Loutelier-Bourhis C, Rayon C, et al. Beta(1,2)-xylose and alpha(1,3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J Biol Chem 2000; 275: 11451-8.
121. Foetisch K, Westphal S, Lauer I, Retzek M, Altmann F, Kolarich D, et al. Biological activity of IgE specific for cross-reactive carbohydrate determinants. J Allergy Clin Immunol 2003; 111: 889-96.
122. Sandrin MS, McKenzie IF. Gal alpha (1,3)Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev 1994; 141: 169-90.
123. Hamako J, Matsui T, Ozeki Y, Mizuochi T, Titani K. Comparative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian species. Comp Biochem Physiol B 1993; 106: 949-54.
124. http: //www.bioc.aecom.yu.edu/bgmut/index.htm
125. Fujii S, Nishiura T, Nishikawa A, Miura R, Taniguchi N. Structural heterogeneity of sugar chains in immunoglobulin G. Conformation of immunoglobulin G molecule and substrate specificitiesof glycosyltransferases. J Biol Chem 1990; 265: 6009-18.
126. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48: 899-907.
127. Bakker H, Bardor M, Molthoff JW, Gomord V, Elbers I, Stevens LH, et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad Sci USA 2001; 98: 2899-904.
128. Shah MM, Fujiyama K, Flynn CR, Joshi L. Sialylated endogenous glycoconjugates in plant cells. Nature Biotechnol 2003; 21: 1470-1.
129. Cone RA, Whaley KJ. Topical application of antibodies for contraception and for prophylaxis against sexually transmitted diseases. US patent 6, 2002; 355, 235, 2002.
130. Bouquin T, Thomsen M, Nielsen LK, Green TH, Mundy J, Hanefeld D. Human anti-rhesus D IgG1 antibody produced in transgenic plants. Transgenic Res 2002; 11(2): 115-22.
131. Camperi SA, Iannucci NB, Albanesi GJ, Oggero M, Eberhardt M, Etcheverrigaray A, et al. Monoclonal antibody purification by affinity chromatography with ligands derived from the screening of peptide combinatory libraries. Biotechnol Lett 2003; 25: 1545-8.
132. Scheller J, Henggeler D, Viviani A, Conrad U. Purification of spider silk-elastin from transgenic plants and application for human chondrocyte proliferation. Transgenic Res (in press).
133. Borisjuk NV, Borisjuk LG, Logendra S, Petersen F, Gleba Y, Raskin I. Production of recombinant proteins in plant root exudates. Nature Biotechnol 1999; 17: 466-9.
134. Komarnytsky S, Borisjuk NV, Borisjuk LG, Alam MZ, Raskin I. Production of recombinant proteins in tobacco guttation fluid. Plant Physiol 2000; 124: 927-33.
135. Stein KE, Webber KO. The regulation of biologic products derived from bioengineered plants. Curr Opin Biotechnol 2001; 12: 308-11.
136. Miele L. Plants as bioreactors for biopharmaceuticals: regulatory considerations. Trends Biotechnol 1997; 15: 45-50.
137. Menessa R, Nguyen V, Jevnikar A, Brandle J. A self-contained system for the field production of plant recombinant interlelikin-10. Mol Breed 2001; 8: 177-185.
138. Gressl J. Tandem constructs: preventing the rise of superweeds. Trends Biotechnol 1999, 17: 361-366.
139. Commandeur U, Twyman RM, Fischer R. The biosafety of molecular farming in plants. AgBiotechNet 2003; 5: ABN 110.
140. Mascial PN, Flavell RB. Safe and acceptable strategies for producing foreign molecules in plants. Curr Opin Plant Biol 2004: 7: (in press).
141. Kuroda Y, Nakata M, Makino A, Matsumoto A, Ohashi K, Itahashi K, et al. Structural Studies on IgG oligosaccharides of patients with primary Sjögren's syndrome. Glycoconj J 2002; 19: 23-31.
142. Youings A, Chang SC, Dwek RA, Scragg IG. Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J 1996; 314: 621-30.
143. Fleming SC, Smith S, Knowles D, Skillen A, Self CH. Increased sialylation of oligosaccharides on IgG paraproteins - a potential new tumour marker in multiple myeloma. J Clin Pathol. 1998; 51: 825-30.
144. Routier FH, Hounsell EF, Rudd PM, Takahashi N, Bond A, Hay FC, et al. Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods. J Immunol Methods 1998; 213: 113-30.
145. Francisco JA, Gawlak SL, Miller M, Bathe J, Russell D, Chace D, et al. Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture. Bioconjug Chem 1997; 8: 708-13.
146. Korhonen H, Pihlanto A. Food-derived bioactive peptides - opportunities for designing future foods. Curr Pharm Design 2003; 9(16) 1297-308.
147. Pellegrini A. Antimicrobial peptides from food proteins. Curr Pharm Design 2003; 9(16): 1225-38.
148. Rodriguez-Concepcion M. The MEP pathway: a new target for the development of herbicides, antibiotics and antimalarial drugs. Curr Pharm Design 2004; 10(19): 2391-400.